0511 GMT - Raffles Medical Group's profitability is likely to improve, DBS Group Research analysts say in a research report. Gestational losses at its Shanghai and Chongqing hospitals in China should narrow, with the healthcare service provider executing plans to achieve Ebitda breakeven by 2026, the analysts say. Top-line growth in its insurance business should drive operating leverage and boost margins, barring significant deviations in the claims ratio, the analysts say. Raffles Medical has also revised its dividend policy to pay out at least 50% of sustainable earnings annually, the analysts add. DBS upgrades Raffles Medical to buy from hold and raises the stock's target price to S$1.12 from S$0.97. Shares are 1.1% higher at S$0.915. (ronnie.harui@wsj.com)
(END) Dow Jones Newswires
February 26, 2025 00:12 ET (05:12 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。